Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why Is Endo International (ENDP) Down 15% Since its Last Earnings Report?

Endo International (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod

    BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.

      3 Sell-Rated Drug Stocks Investors Should Avoid for Now

      Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.

        Options Traders Expect Huge Moves in Endo International (ENDP) Stock

        Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.

          BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y

          BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.

            Kohl???s, Endo International and Costco as Zacks Bull and Bear of the Day

            Kohl???s, Endo International and Costco as Zacks Bull and Bear of the Day

              Madeleine Johnson headshot

              Bear of the Day: Endo International (ENDP)

              Litigation has hit this opioid drug maker hard. Is there any chance for a rebound?

                What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?

                BioDelivery's (BDSI) lead drugs Belbuca and Bunavail look promising to deliver an earnings beat in Q4.

                  Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4

                  Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.

                    New Strong Sell Stocks for February 28th

                    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                      Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

                      Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

                        Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?

                        Endo International (ENDP) lost 35% in the past year mired by controversy related to Opana ER and weaknesses in both the businesses.

                          Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse

                          Endo (ENDP) announced that it received a subpoena from the Florida authorities in connection with products related to opioid misuse.

                            Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

                            Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.

                              BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

                              BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.

                                Implied Volatility Surging for Endo (ENDP) Stock Options

                                Endo (ENDP) needs investors to pay close attention to the stock based on moves in the options market lately.

                                  Should Value Investors Consider Endo International (ENDP) Stock?

                                  Lets put Endo International plc (ENDP) stock into this equation and find out if it is a good choice for value-oriented investors right now.

                                    Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?

                                    Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.

                                      New Strong Sell Stocks for September 11th

                                      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                        New Strong Sell Stocks for August 31st

                                        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                          Will Endo (ENDP) Continue to Disappoint Investors in 2017?

                                          Endo (ENDP) a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, is under significant pressure due to intensifying consortium pricing pressures and additional competitive entrants and product discontinuations.

                                            BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End

                                            BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.

                                              Endo International (ENDP) Jumps: Stock Rises 6.9%

                                              Endo International (ENDP) was a big mover last session, as the company saw its shares rise almost 7% on the day amid huge volumes.

                                                BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls

                                                BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.

                                                  Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered

                                                  Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.